iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics. Through this platform, iBio offers contract development and manufacturing services (CDMO) to biopharmaceutical partners seeking flexible, modular production capacity. Its iBio Launch™ modular manufacturing units are engineered to accommodate everything from pilot-scale candidate evaluation to multi-metric commercial output, reducing the time and capital investment typically required for biologics production facilities.

In addition to its CDMO business model, iBio maintains an internal pipeline of vaccine candidates and therapeutic proteins. The company has engaged in collaborative research programs with academic institutions and government agencies to advance vaccine development against infectious diseases. These strategic alliances underscore iBio’s commitment to leveraging plant-based expression systems for rapid response to emerging health threats.

Founded in 1993 and headquartered in Bryan, Texas, iBio serves clients and partners across North America, Europe and Asia through its Texas-based facilities and global network of contract partners. Led by an experienced management team with deep roots in biopharmaceutical development, the company continues to expand its technological capabilities and manufacturing footprint to meet growing demand for next-generation biologics.

Key Stats

• Today's Range: $0.82 to $0.87
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: $0.56 to $6.89
• Volume: 347,220 shs
• Average Volume: 1.50 million shs
• Market Capitalization: $16.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 38% of companies evaluated by MarketBeat, and ranked 740th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

iBio has a consensus price target of $5.00, representing about 500.4% upside from its current price of $0.83.

Amount of Analyst Coverage

iBio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iBio are expected to decrease in the coming year, from ($1.74) to ($2.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iBio is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iBio is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IBIO.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

iBio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for iBio this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for IBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added iBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.58% of the stock of iBio is held by insiders.

Percentage Held by Institutions

Only 7.90% of the stock of iBio is held by institutions.

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.45 at the beginning of 2025. Since then, IBIO stock has decreased by 66.0% and is now trading at $0.8328.

How were iBio's earnings last quarter?

iBio, Inc. (NYSE:IBIO) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.46) earnings per share for the quarter, hitting the consensus estimate of ($0.46).

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Fastly (FSLY), Fortinet (FTNT), Snowflake (SNOW), Tesla (TSLA), Arbor Realty Trust (ABR) and Accenture (ACN).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/10/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IBIO
• Previous Symbol: NYSE:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: 302-355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iBio: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +500.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.91 million
• Net Margins: N/A
• Pretax Margin: -3,795.73%
• Return on Equity: -73.15%
• Return on Assets: -45.51%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.76
• Quick Ratio: 1.76

Sales & Book Value

• Annual Sales: $375 thousand
• Price / Sales: 43.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 19,655,000
• Free Float: 9,818,000
• Market Cap: $16.37 million
• Optionable: N/A
• Beta: 0.86